Anti-inflammatory and antioxidant therapies for chagasic myocarditis: a systematic review

Freitas, Dayanne S; Godinho, Andressa S S; Mondêgo-Oliveira, Renata; Cardoso, Flávia de Oliveira; Abreu-Silva, Ana Lúcia; Silva, Lucilene A.

doi:10.1017/s0031182020000153

Cited by 5 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is interesting as myeloid-type innate immune cells provide an immune response of metabolic reprogramming and are targets of parasitic infections such as Trypanosoma cruzi, which can compromise the liver, spleen, and lymph nodes, and cause chronic brain and cardiac inflammation that can be fatal to the individual [9]. Treatment with this drug is reflected in the improvement of cardiac function [12]. In vitro mouse models have shown that if there is an activator of SIRT1, it can suppress the oxidative stress and inflammation characteristic of the chronic phase of Chagas disease.…”

Section: Resveratrol and Sirtuinmentioning

confidence: 99%

"Therapeutic Uses of Resveratrol Compound in Chagas Disease - A Literature Review"

Silva

2022

BJSTR

View full text Add to dashboard Cite

Chagas disease is a parasitic disease caused by Trypanosoma cruzi and is also a highly neglected tropical disease. In chronic stages of the disease there may be brain and cardiac inflammation that can lead to death. The nitroxidative effect of cells in response to infection contributes to disease progression by inducing tissue damage. In this systematic review, experiments are presented and discussed that seek to understand the use of antioxidants to combat harmful ROS (reactive oxygen species), in order to reduce oxidative damage to tissue during disease progression. One of the viable forms of therapy to control the chronic form of Chagas Disease are sirtuins, molecules that are part of histone deacetylases (HDAC) of the class III family. The compound presented in this review is resveratrol, which is a natural polyphenol found in grape seeds that acts as a sirtuin 1 agonist (SIRT1), this compound activates SIRT1 during parasitic infections. Studies on SIRT1 are linked to its agonist resveratrol and present a good future perspective for new trypanocidal drugs, as they have a relationship with oxidative stress and an anti-inflammatory effect related to neuroinflammation and cardioprotective effects by preventing cardiac hypertrophy. However, there is a need for clinical tests and studies of Resveratrol in humans to further explore the anti-inflammatory effects that the compound has during the oxidative stress caused by T. cruzi infection. Consequently, this would enable the use of antioxidants, such as Resveratrol, in the treatment of Chagas disease. drugs to control this late inflammation have been researched, since

show abstract

Section: Resveratrol and Sirtuinmentioning

confidence: 99%

"Therapeutic Uses of Resveratrol Compound in Chagas Disease - A Literature Review"

Silva

2022

BJSTR

View full text Add to dashboard Cite

show abstract

“…Ameliorating cardiac inflammation and oxidative damage through treatment with a SIRT1 agonist improved cardiac function, without altering cardiac parasite burden or cardiac fibrosis [174]. Antioxidant treatments are also being tested in patients, with some promise in late-stage disease, though most studies did not assess functional improvement (see [175] for a systematic review).…”

Section: Immune Modulation Through Metabolism To Improve Chagas Disea...mentioning

confidence: 99%

Small molecule mediators of host-T. cruzi-environment interactions in Chagas disease

Kwakye-Nuako,

Middleton,

McCall

2024

PLoS Pathog

View full text Add to dashboard Cite

Small molecules (less than 1,500 Da) include major biological signals that mediate host-pathogen-microbiome communication. They also include key intermediates of metabolism and critical cellular building blocks. Pathogens present with unique nutritional needs that restrict pathogen colonization or promote tissue damage. In parallel, parts of host metabolism are responsive to immune signaling and regulated by immune cascades. These interactions can trigger both adaptive and maladaptive metabolic changes in the host, with microbiome-derived signals also contributing to disease progression. In turn, targeting pathogen metabolic needs or maladaptive host metabolic changes is an important strategy to develop new treatments for infectious diseases. Trypanosoma cruzi is a single-celled eukaryotic pathogen and the causative agent of Chagas disease, a neglected tropical disease associated with cardiac and intestinal dysfunction. Here, we discuss the role of small molecules during T. cruzi infection in its vector and in the mammalian host. We integrate these findings to build a theoretical interpretation of how maladaptive metabolic changes drive Chagas disease and extrapolate on how these findings can guide drug development.

show abstract

Current Treatment of Chagas Disease

Álvarez-Hernández

Castro-Rico

García-Rodríguez-Arana

et al. 2020

Curr Treat Options Infect Dis

View full text Add to dashboard Cite

Anti-inflammatory and antioxidant therapies for chagasic myocarditis: a systematic review

Cited by 5 publications

References 38 publications

"Therapeutic Uses of Resveratrol Compound in Chagas Disease - A Literature Review"

"Therapeutic Uses of Resveratrol Compound in Chagas Disease - A Literature Review"

Small molecule mediators of host-T. cruzi-environment interactions in Chagas disease

Current Treatment of Chagas Disease

Contact Info

Product

Resources

About